Co-stimulatory molecule clusters correlate with survival, immune infiltration, and tumor mutation burden in non-small cell lung cancer

References

• Altz LSZ, Hi S, Baselga J, Razavi P, Ca K, Yaeger R, Nh S, Gy K, Rp D, Ladanyi M, et al. 2019. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 51:202–206.
   PubMed Web of Science ®Google Scholar
• Anichini A, Perotti VE, Sgambelluri F, Mortarini R. 2020. Immune escape mechanisms in non small cell lung cancer. Cancers (Basel). 12:3605.
   PubMed Web of Science ®Google Scholar
• Aye L, Song X, Yang J, Hu L, Sun X, Zhou J, Liu Q, Yu H, Wang D. 2021. Identification of a costimulatory molecule gene signature to predict survival and immunotherapy response in head and neck squamous cell carcinoma. Front Cell Dev Biol. 9:695533.
   PubMed Web of Science ®Google Scholar
• Azuma M. 2019. Co-signal molecules in T-cell activation: historical overview and perspective. Adv Exp Med Biol. 1189:3–23.
   PubMedGoogle Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424.
   PubMed Web of Science ®Google Scholar
• Cao M, Yan H, Han X, Weng L, Wei Q, Sun X, Lu W, Wei Q, Ye J, Cai X, et al. 2019. Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth. J Immunother Cancer. 7:326.
   PubMed Web of Science ®Google Scholar
• Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E. 2012. Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol. 2012:926321.
   PubMed Web of Science ®Google Scholar
• Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, Tamragouri K, Rhee K, Mohindra N, et al. 2019. Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer. Oncologist. 24:820–828.
   PubMed Web of Science ®Google Scholar
• Duma N, Santana-Davila R, Molina JR. 2019. Non-Small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 94:1623–1640.
   PubMed Web of Science ®Google Scholar
• Eguren-Santamaria I, Sanmamed MF, Goldberg SB, Kluger HM, Idoate MA, Lu BY, Corral J, Schalper KA, Herbst RS, Gil-Bazo I. 2020. PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice. Clin Cancer Res. 26:4186–4197.
   PubMed Web of Science ®Google Scholar
• Fife BT, Bluestone JA. 2008. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 224:166–182.
   PubMed Web of Science ®Google Scholar
• Ge S, Hua X, Chen J, Xiao H, Zhang L, Zhou J, Liang C, Tai S. 2021. Identification of a costimulatory molecule-related signature for predicting prognostic risk in prostate cancer. Front Genet. 12:666300.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. 2018. The biology and management of non-small cell lung cancer. Nature. 553:446–454.
   PubMed Web of Science ®Google Scholar
• Hua X, Ge S, Zhang J, Xiao H, Tai S, Yang C, Zhang L, Liang C. 2021. A costimulatory molecule-related signature in regard to evaluation of prognosis and immune features for clear cell renal cell carcinoma. Cell Death Discov. 7:252.
   PubMed Web of Science ®Google Scholar
• Inaguma S, Lasota J, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Schrump DS, et al. 2020. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness. J Pathol. 250:205–216.
   PubMed Web of Science ®Google Scholar
• Jacobs J, Deschoolmeester V, Rolfo C, Zwaenepoel K, Van Den Bossche J, Deben C, Silence K, De Haard H, Hermans C, Rottey S, et al. 2017. Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy. Oncotarget. 8:74058–74067.
   PubMedGoogle Scholar
• Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S, Lardon F, Smits E, Pauwels P. 2015. CD70: an emerging target in cancer immunotherapy. Pharmacol Ther. 155:1–10.
   PubMed Web of Science ®Google Scholar
• Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, Li J, Li F, Tan HB. 2020. Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett. 470:126–133.
   PubMed Web of Science ®Google Scholar
• Magee CN, Boenisch O, Najafian N. 2012. The role of costimulatory molecules in directing the functional differentiation of alloreactive T helper cells. Am J Transplant. 12:2588–2600.
   PubMed Web of Science ®Google Scholar
• Nagai S, Azuma M. 2019. The CD28-B7 family of co-signaling molecules. Adv Exp Med Biol. 1189:25–51.
   PubMed Web of Science ®Google Scholar
• Pacella I, Grimaldi A, Piconese S. 2020. Assessment of lipid load in tumor-infiltrating Tregs by flow cytometry. Methods Enzymol. 632:283–294.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. 2016. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 375:1823–1833.
   PubMed Web of Science ®Google Scholar
• Reichel D, Tripathi M, Perez JM. 2019. Biological effects of nanoparticles on macrophage polarization in the tumor microenvironment. Nanotheranostics. 3:66–88.
   PubMedGoogle Scholar
• Sasidharan Nair V, Elkord E. 2018. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol. 96:21–33.
   PubMed Web of Science ®Google Scholar
• Schorer M, Kuchroo VK, Joller N. 2019. Role of co-stimulatory molecules in T helper cell differentiation. Adv Exp Med Biol. 1189:153–177.
   PubMed Web of Science ®Google Scholar
• So T, Ishii N. 2019. The TNF-TNFR family of co-signal molecules. Adv Exp Med Biol. 1189:53–84.
   PubMed Web of Science ®Google Scholar
• Suster DI, Mino-Kenudson M. 2020. Molecular pathology of primary non-small cell lung cancer. Arch Med Res. 51:784–798.
   PubMed Web of Science ®Google Scholar
• Watts TH. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 23:23–68.
   PubMed Web of Science ®Google Scholar
• Wu K, Lin K, Li X, Yuan X, Xu P, Ni P, Xu D. 2020. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol. 11:1731.
   PubMed Web of Science ®Google Scholar
• Xia L, Liu Y, Wang Y. 2019. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist. 24:S31–s41.
   PubMed Web of Science ®Google Scholar
• Yang S, Wei W, Zhao Q. 2020. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci. 16:1767–1773.
   PubMed Web of Science ®Google Scholar
• Ye L JK, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, He Y, Zhou C. 2020. CD137, an attractive candidate for the immunotherapy of lung cancer. Cancer Sci. 111:1461–1467.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang Z, Sun N, Zhang Z, Zhang G, Wang F, Luo Y, Che Y, He J. 2020a. Identification of a costimulatory molecule-based signature for predicting prognosis risk and immunotherapy response in patients with lung adenocarcinoma. Oncoimmunology. 9:1824641.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen J, Cheng T, Yang H, Li H, Pan C. 2020b. Identification of the key genes and characterizations of tumor immune microenvironment in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). J Cancer. 11:4965–4979.
   PubMed Web of Science ®Google Scholar